Abstract:Background: Aberrant expression of transforming growth factorβ1 (TGF-β1) is associated with renal cell carcinoma (RCC) progression by inducing cancer metastasis. However, the downstream effector(s) in TGF-β signaling pathway that is involved in RCC progression is not fully characterized. Methods: SPARC was identified as a potential downstream target gene in TGF-β-induced cell invasion by applying microarray analysis, qRT-PCR and Western blot. In vitro and in vivo assays were subsequently performed to validate the role of SPARC in RCC. SPARC expression profile in RCC tissues and its correlation with clinical data were also examined.Findings: We demonstrate that elevated SPARC is associated with metastatic RCC; SPARC gene expression can be induced by TGF-β1 via Snail. Clinically, the expression of these two genes is positively correlated in RCC patient specimens. Furthermore, elevated SPARC expression is found in all the subtypes of RCC and positively correlated with RCC stage and grade. In contrast, SPARC expression is inversely correlated with overall and disease-free survival of RCC patients, suggesting SPARC as a potent prognostic marker of RCC patient survival. Knocking down SPARC significantly inhibits RCC cell invasion and metastasis both in vitro and in vivo. Similarly, in vitro cell invasion can be diminished by using specific monoclonal antibody. Mechanistically, SPARC activate AKT pathway leading to elevated expression of matrix metalloproteinase-2 (MMP2) that can facilitate RCC invasion.Interpretation: Our data support that SPARC regulated by TGF-β is a key driver for RCC metastases, therefore, it becomes a potent therapeutic target.Funding Statement: This study was in part funded by a grant from China Scholarship Council (201508440279) and a grant from Health Commission of Guangdong Province (A2019513). This work was supported in part by the Harold C. Simmons Cancer Center through an NCI Cancer Center Support Grant, 1P30 CA142543 and The Department of Radiology.Declaration of Interests: All the authors do not have any conflict of interest.Ethics Approval Statement: The Institutional Review Board approved clinical specimen procurement protocol for this study and informed consent was obtained from patients. Animal work described in this manuscript has been approved and conducted under the oversight of the UTSW Institutional Animal Care and Use Committee.

Notch Activation Promotes Bone Metastasis Via SPARC Inhibition in Adenoid Cystic Carcinoma

Notch Activation Leads to Loss of Myoepithelial Differentiation and Poor Outcome in Solid Adenoid Cystic Carcinoma.

The Role and Mechanism of SPARC in Renal Cancer Metastasis

SPARC Promotes the Proliferation and Metastasis of Oral Squamous Cell Carcinoma by PI3K/AKT/PDGFB/PDGFRβ Axis

Notch Signaling Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis in Adenoid Cystic Carcinoma.

SPARC is a Key Mediator of TGF‐β‐induced Renal Cancer Metastasis

Targeting SPARC by Lentivirus-Mediated RNA Interference Inhibits Cervical Cancer Cell Growth and Metastasis

Inhibiting immune escape in lung adenocarcinoma: the role of SPARC in suppressing CD276 function

Correlation Between Secreted Protein Acidic and Rich in Cysteine Protein Expression and the Prognosis of Postoperative Patients Exhibiting Esophageal Squamous Cell Carcinoma

Secreted Protein Acidic and Rich in Cysteine (SPARC) is Associated with Nasopharyngeal Carcinoma Metastasis and Poor Prognosis

The Notch Pathway Promotes Osteosarcoma Progression through Activation of Ephrin Reverse Signaling.

Sparc Is A Key Regulator Of Proliferation, Apoptosis And Invasion In Human Ovarian Cancer

SPARC Expression in Tumor Microenvironment Induces Partial Epithelial‐to‐mesenchymal Transition of Esophageal Adenocarcinoma Cells Via Cooperating with TGF‐β Signaling

Sparc is Associated with Gastric Cancer Progression and Poor Survival of Patients

SPARC in Tumor Pathophysiology and As a Potential Therapeutic Target

SPARC is a Novel Prognostic Biomarker for Ovarian Cancer and Associated with Immune Signatures and Drug Response

SPARCL1 Suppresses Osteosarcoma Metastasis and Recruits Macrophages by Activation of Canonical WNT/β-catenin Signaling Through Stabilization of the WNT–receptor Complex

Secreted Protein Acidic and Rich in Cysteine Expression in Human Colorectal Cancer Predicts Postoperative Prognosis

SPARC Acts As a Mediator of TGF‐β1 in Promoting Epithelial‐to‐mesenchymal Transition in A549 and H1299 Lung Cancer Cells

The role of SPARC expression in pancreatic cancer progression and patient survival

Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma